Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells

  • Kim, Yeong Hoon (Department of Ophthalmology, College of Medicine, The Catholic University of Korea) ;
  • Bhatt, Lokraj (Department of Parasitology, College of Medicine, The Catholic University of Korea) ;
  • Ahn, Hye-Jin (Department of Parasitology, College of Medicine, The Catholic University of Korea) ;
  • Yang, Zhaoshou (Department of Parasitology, College of Medicine, The Catholic University of Korea) ;
  • Lee, Won-Kyu (Osong Medical Innovation Foundation) ;
  • Nam, Ho-Woo (Department of Parasitology, College of Medicine, The Catholic University of Korea)
  • Received : 2017.07.25
  • Accepted : 2017.09.26
  • Published : 2017.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

The effects of tyrosine kinase inhibitors (TKIs) were evaluated on growth inhibition of intracellular Toxoplasma gondii in host ARPE-19 cells. The number of tachyzoites per parasitophorous vacuolar membrane (PVM) was counted after treatment with TKIs. T. gondii protein expression was assessed by western blot. Immunofluorescence assay was performed using Programmed Cell Death 4 (PDCD4) and T. gondii GRA3 antibodies. The TKIs were divided into 3 groups; non-epidermal growth factor receptor (non-EGFR), anti-human EGFR 2 (anti-HER2), and anti-HER2/4 TKIs, respectively. Group I TKIs (nintedanib, AZD9291, and sunitinib) were unable to inhibit proliferation without destroying host cells. Group II TKIs (lapatinib, gefitinib, erlotinib, and AG1478) inhibited proliferation up to 98% equivalent to control pyrimethamine ($5{\mu}M$) at $20{\mu}M$ and higher, without affecting host cells. Group III TKIs (neratinib, dacomitinib, afatinib, and pelitinib) inhibited proliferation up to 98% equivalent to pyrimethamine at $1-5{\mu}M$, but host cells were destroyed at $10-20{\mu}M$. In Group I, TgHSP90 and SAG1 inhibitions were weak, and GRA3 expression was moderately inhibited. In Group II, TgHSP90 and SAG1 expressions seemed to be slightly enhanced, while GRA3 showed none to mild inhibition; however, AG1478 inhibited all proteins moderately. Protein expression was blocked in Group III, comparable to pyrimethamine. PDCD4 and GRA3 were well localized inside the nuclei in Group I, mildly disrupted in Group II, and were completely disrupted in Group III. This study suggests the possibility of a vital T. gondii TK having potential HER2/4 properties, thus anti-HER2/4 TKIs may inhibit intracellular parasite proliferation with minimal adverse effects on host cells.

Keywords

References

  1. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000; 30: 1217-1258. https://doi.org/10.1016/S0020-7519(00)00124-7
  2. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA community-based Uveitis study group. Am J Ophthalmol 1996; 121: 35-46. https://doi.org/10.1016/S0002-9394(14)70532-X
  3. Pradhan E, Bhandari S, Gilbert RE, Stanford M. Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database Syst Rev 2016; 20: CD002218.
  4. Yang Z, Ahn HJ, Park YH, Nam HW. Afatinib reduces STAT6 signaling of host ARPE-19 cells infected with Toxoplasma gondii. Korean J Parasitol 2016; 54: 31-38. https://doi.org/10.3347/kjp.2016.54.1.31
  5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934. https://doi.org/10.1126/science.1075762
  6. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69: 373-398. https://doi.org/10.1146/annurev.biochem.69.1.373
  7. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267: 1782-1788. https://doi.org/10.1126/science.7892601
  8. Muniz-Feliciano L, Van Grol J, Portillo JA, Liew L, Liu B, Carlin CR, Carruthers VB, Matthews S, Subauste CS. Toxoplasma gondiiinduced activation of EGFR prevents autophagy protein-mediated killing of the parasite. PLoS Pathog 2013; 9: e1003809. https://doi.org/10.1371/journal.ppat.1003809
  9. Peixoto L, Chen F, Harb OS, Davis PH, Beiting DP, Brownback CS, Ouloguem D, Roos DS. Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses. Cell Host Microbe 2010; 8: 208-218. https://doi.org/10.1016/j.chom.2010.07.004
  10. Wei S, Marches F, Daniel B, Sonda S, Heidenreich K, Curiel T. Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. Int J Parasitol 2002; 32: 969-977. https://doi.org/10.1016/S0020-7519(02)00061-9
  11. Brumlik MJ, Wei S, Finstad K, Nesbit J, Hyman LE, Lacey M, Burow ME, Curiel TJ. Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii. Int J Parasitol 2004; 34: 1245-1254. https://doi.org/10.1016/j.ijpara.2004.07.007
  12. Huang H, Ma YF, Bao Y, Lee H, Lisanti MP, Tanowitz HB, Weiss LM. Molecular cloning and characterization of mitogen-activated protein kinase 2 in Toxoplasma gondii. Cell Cycle 2011; 10: 3519-3526. https://doi.org/10.4161/cc.10.20.17791
  13. Donald RG, Allocco J, Singh SB, Nare B, Salowe SP, Wiltsie J, Liberator PA. Toxoplasma gondii cyclic GMP-dependent kinase: chemotherapeutic targeting of an essential parasite protein kinase. Eukaryot Cell 2002; 1: 317-328. https://doi.org/10.1128/EC.1.3.317-328.2002
  14. Kurokawa H, Kato K, Iwanaga T, Sugi T, Sudo A, Kobayashi K, Gong H, Takemae H, Recuenco FC, Horimoto T, Akashi H. Identification of Toxoplasma gondii cAMP dependent protein kinase and its role in the tachyzoite growth. PLoS One 2011; 6: e22492. https://doi.org/10.1371/journal.pone.0022492
  15. Yang Z, Ahn HJ, Nam HW. Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells. Korean J Parasitol 2014; 52: 439-441. https://doi.org/10.3347/kjp.2014.52.4.439
  16. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39. https://doi.org/10.1038/nrc2559
  17. Sun K, Broms J, Lavander M, Gurram BK, Enquist PA, Andersson CD, Elofsson M, Sjostedt A. Screening for inhibition of Vibrio cholerae VipA-VipB interaction identifies small-molecule compounds active against type VI secretion. Antimicrob Agents Chemother 2014; 58: 4123-4130. https://doi.org/10.1128/AAC.02819-13
  18. Lepri S, Nannetti G, Muratore G, Cruciani G, Ruzziconi R, Mercorelli B, Palu G, Loregian A, Goracci L. Optimization of smallmolecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds. J Med Chem 2014; 57: 4337-4350. https://doi.org/10.1021/jm500300r
  19. Belfort Jr R, Silveira C, Muccioli C. Ocular Toxoplasmosis A2. In Sadda SR, Hinton DR, Schachat AP, Sadda SR, Wilkinson CP, Wiedemann P, Schachat AP eds, Retina. 15th ed. London, UK. WB Saunders. 2013, pp 1494-1499.
  20. Carrion-Carrion C, Morales-Suarez-Varela MM, Llopis-Gonzalez A. Fatal Stevens-Johnson syndrome in an AIDS patient treated with sulfadiazine. Ann Pharmacother 1999; 33: 379-380. https://doi.org/10.1345/aph.18068
  21. Wei F, Wang W, Liu Q. Protein kinases of Toxoplasma gondii: functions and drug targets. Parasitol Res 2013; 112: 2121-2129. https://doi.org/10.1007/s00436-013-3451-y
  22. Majem M, Pallares C. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clin Transl Oncol 2013; 15: 343-357. https://doi.org/10.1007/s12094-012-0964-2
  23. Wang X, Batty KM, Crowe PJ, Goldstein D, Yang JL. The Potential of panHER Inhibition in Cancer. Front Oncol 2015; 5: 2.
  24. Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opinion on Therapeutic Targets 2003; 7: 215-234. https://doi.org/10.1517/14728222.7.2.215
  25. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478. https://doi.org/10.4161/cbt.2.5.446
  26. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774-4782. https://doi.org/10.1158/0008-5472.CAN-07-6307
  27. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-1061. https://doi.org/10.1158/2159-8290.CD-14-0337
  28. Ross HJ, Blumenschein GR, Jr., Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010; 16: 1938-1949. https://doi.org/10.1158/1078-0432.CCR-08-3328
  29. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2008; 7: 1846-1850. https://doi.org/10.1158/1535-7163.MCT-08-0168
  30. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, Averbuch S, Baselga J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003; 9: 1274-1283.
  31. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001; 61: 7196-7203.
  32. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60: 5887-5894.
  33. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, Wissner A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64: 3958-3965. https://doi.org/10.1158/0008-5472.CAN-03-2868
  34. Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol 2011; 7: 817-825. https://doi.org/10.2217/fon.11.62
  35. Nunes M, Shi C, Greenberger LM. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB- 569, in tumor cells and normal human keratinocytes. Mol Cancer Ther 2004; 3: 21-27.
  36. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Janne PA. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67: 11924-11932. https://doi.org/10.1158/0008-5472.CAN-07-1885
  37. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003; 284: 2-13. https://doi.org/10.1016/S0014-4827(02)00105-2
  38. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137. https://doi.org/10.1038/35052073
  39. Burgess AW, Cho H-S, Eigenbrot C, Ferguson KM, Garrett TPJ, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12: 541-552. https://doi.org/10.1016/S1097-2765(03)00350-2
  40. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887-8895.
  41. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284: 54-65. https://doi.org/10.1016/S0014-4827(02)00101-5
  42. Nam HW. GRA proteins of Toxoplasma gondii: maintenance of host-parasite interactions across the parasitophorous vacuolar membrane.. Korean J Parasitol 2009; 47 (Suppl): 29-37. https://doi.org/10.3347/kjp.2009.47.S.S29
  43. Eto K, Goto S, Nakashima W, Ura Y, Abe S. Loss of programmed cell death 4 induces apoptosis by promoting the translation of procaspase-3 mRNA. Cell Death Differ 2012; 19: 573-581. https://doi.org/10.1038/cdd.2011.126
  44. Rosowski EE, Nguyen QP, Camejo A, Spooner E, Saeij JP. Toxoplasma gondii inhibits gamma interferon (IFN-$\gamma$)- and IFN-${\beta}$-induced host cell STAT1 transcriptional activity by increasing the association of STAT1 with DNA. Infect Immun 2014; 82: 706-719. https://doi.org/10.1128/IAI.01291-13